C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/12 (2006.01) A61K 38/17 (2006.01) A61K 48/00 (2006.01) C07K 7/06 (2006.01) C07K 14/47 (2006.01) G01N 33/50 (2006.01) G01N 33/53 (2006.01) G01N 33/68 (2006.01) A61K 39/00 (2006.01)
Patent
CA 2383737
Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA- type of the patient to be treated or tested are described.
L'invention concerne des peptides et des polypeptides dérivés du polypeptide MUC-1 pouvant activer la réponse des lymphocytes T cytotoxiques (CTL), des analogues de ces peptides et polypeptides, des séquences nucléotidiques codant pour ces peptides et polypeptides et leurs utilisations thérapeutiques. L'invention donne également des indications permettant de sélectionner les polypeptides MUC-1 antigéniques minimes appropriés en fonction du type de HLA du patient allant être soumis à un traitement ou à des tests.
Acres Bruce
Heukamp Lukas Carl
Melief Cornelis Johanna Maria
Offringa Rienk
Taylor-Papadimitriou Joyce
Imperial Cancer Research Technology Ltd.
Ridout & Maybee Llp
Transgene S.a.
LandOfFree
Muc-1 derived peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Muc-1 derived peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Muc-1 derived peptides will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1703257